High hopes for RANKL: Will the mouse model live up to its promise?

Breast Cancer Research

Volumn 13, Issue 1, 2011, Pages

  Tanos, Tamara ^a   Brisken, Cathrin ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; DIMETHYLBENZ[A]ANTHRACENE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; OSTEOCLAST DIFFERENTIATION FACTOR; PROGESTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; DRUG APPROVAL; HORMONE ACTION; LUNG METASTASIS; MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEIN EXPRESSION; ANIMAL; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; HUMAN; METABOLISM; NOTE; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; PROGESTINS; RANK LIGAND;

EID: 84860389654     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2805     Document Type: Article

References (15)

1. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993, 15:36-47.
2. Ramakrishnan R, Khan SA, Badve S. Morphological changes in breast tissue with menstrual cycle. Mod Pathol 2002, 15:1348-1356. 10.1097/01.MP.0000039566.20817.46, 12481017.
3. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G, . WHI Investigators Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009, 360:573-587. 10.1056/NEJMoa0807684, 19196674, WHI Investigators.
4. Nakashima T, Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 2009, 29:555-567. 10.1007/s10875-009-9316-6, 19585227.
5. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50. 10.1016/S0092-8674(00)00103-3, 11051546.
6. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696. 10.1038/nature04524, 16572175.
7. Brisken C, Ayyannan A, Nguyen C, Heineman A, Reinhardt F, Tan J, Dey SK, Dotto GP, Weinberg RA. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell 2002, 3:877-887. 10.1016/S1534-5807(02)00365-9, 12479812.
8. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 2003, 100:9744-9749. 187836, 12897242, 10.1073/pnas.1732707100.
9. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107:2989-2994. 2840294, 20133621, 10.1073/pnas.0915148107.
10. Fernandez-Valdivia R, Mukherjee A, Ying Y, Li J, Paquet M, DeMayo FJ, Lydon JP. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol 2009, 328:127-139. 10.1016/j.ydbio.2009.01.019, 19298785.
11. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R. Progesterone induces adult mammary stem cell expansion. Nature 465:803-807. 10.1038/nature09091, 20445538.
12. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE. Control of mammary stem cell function by steroid hormone signalling. Nature 465:798-802. 10.1038/nature09027, 20383121.
13. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98-102. 10.1038/nature09387, 20881962.
14. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107. 10.1038/nature09495, 20881963.
15. Brisken C, O'Malley B. Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2010, 2:a003178. 10.1101/cshperspect.a003178, 20739412.